GLP-1 half-life: how long semaglutide and tirzepatide stay in your body
Updated · Wren editorial team · sources: FDA prescribing information and peer-reviewed studies
According to the FDA prescribing information, semaglutide (Ozempic, Wegovy, Rybelsus) has a half-life of about 1 week and stays in the circulation for about 5 to 7 weeks after the last dose. Tirzepatide (Mounjaro, Zepbound) has a half-life of about 5 days (5–6 days in people with overweight or obesity). Dulaglutide (Trulicity) is about 5 days, liraglutide (Saxenda, Victoza) about 13 hours, and orforglipron (Foundayo) 29 to 49 hours.
GLP-1 half-lives at a glance
| Active ingredient | Brands | Half-life | Usual dosing |
|---|---|---|---|
| Semaglutide (injection) | Ozempic, Wegovy | About 1 week | Weekly |
| Semaglutide (tablet) | Rybelsus, Wegovy tablets | About 1 week | Daily |
| Tirzepatide | Mounjaro, Zepbound | About 5 days (5–6 days in overweight/obesity) | Weekly |
| Dulaglutide | Trulicity | About 5 days | Weekly |
| Orforglipron | Foundayo | 29–49 hours | Daily |
| Liraglutide | Saxenda, Victoza | About 13 hours | Daily |
What a half-life means in practice
A half-life is the time it takes for the amount of medicine in your body to fall by half. With weekly semaglutide, the level never drops to zero between shots: each new dose lands on top of what's left from earlier doses, and after several weeks at the same dose the level settles into a steady weekly rise and fall. This is why doctors step doses up gradually, and why side effects often show up in the days right after a shot or after a dose increase.
It also explains how long the medicine lingers when you stop. A common pharmacology rule of thumb is that a drug is mostly cleared after about five half-lives — about 5 weeks for semaglutide, which matches the 5 to 7 weeks in the labels.
How Wren estimates your level
Wren uses the published half-life and average absorption for your medicine, plus the dates and doses you log, to draw an estimated curve. It's useful for questions like “is my appetite coming back because I'm at the end of my dose week?” It is always labeled as an estimate: real levels vary from person to person, and Wren never suggests changing your dose.
See where you are in your dose week
Wren draws an estimated medication-level curve from your logged doses and the published half-life for your medicine — clearly labeled as an estimate.
Frequently asked questions
How long does Ozempic stay in your system?
Semaglutide's half-life is about 1 week. The Ozempic label says it is present in the circulation for about 5 weeks after the last dose; the Wegovy label says about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection.
How long does Mounjaro or Zepbound stay in your system?
Tirzepatide's half-life is about 5 days (the Zepbound label says 5–6 days in people with overweight or obesity). As a rule of thumb, a medicine is mostly cleared after about five half-lives, roughly 4 weeks for tirzepatide.
Why are GLP-1 shots weekly but Saxenda daily?
Half-life. Semaglutide, tirzepatide and dulaglutide last about 5–7 days, so a weekly dose keeps a steady level. Liraglutide's half-life is about 13 hours, so it is injected daily.
What is a GLP-1 medication level chart?
A modeled estimate of how much medicine is in your body over time, calculated from your dose dates and the published half-life. It is not a blood test, and individual absorption varies.
Sources
- OZEMPIC (semaglutide) prescribing information — Novo Nordisk via DailyMed (NIH), label effective June 1, 2026
- WEGOVY (semaglutide) prescribing information — Novo Nordisk via DailyMed (NIH), label effective June 18, 2026
- RYBELSUS (oral semaglutide) prescribing information — Novo Nordisk via DailyMed (NIH), label effective January 30, 2026
- MOUNJARO (tirzepatide) prescribing information — Eli Lilly via DailyMed (NIH), label effective August 27, 2026
- ZEPBOUND (tirzepatide) prescribing information — Eli Lilly via DailyMed (NIH), label effective August 28, 2026
- TRULICITY (dulaglutide) prescribing information — Eli Lilly via DailyMed (NIH), label effective June 16, 2026
- SAXENDA (liraglutide) prescribing information — Novo Nordisk via DailyMed (NIH), label effective February 25, 2026
- FOUNDAYO (orforglipron) prescribing information — Eli Lilly via DailyMed (NIH), label effective July 29, 2026